The latter is of clinical relevance, as a panel of three elevated glycan structures (Lewis-type biantennary glycan, Lewis-type triantennary trisialylated glycan) in combination with ovarian cancer-related tumor marker 125 (CA125) has been shown to discriminate between therapy-sensitive and therapy-resistant patients [43]. This evidence concerns the gene MUC16 and ovarian carcinoma.